Author:
Gourgou-Bourgade S.,Cameron D.,Poortmans P.,Asselain B.,Azria D.,Cardoso F.,A'Hern R.,Bliss J.,Bogaerts J.,Bonnefoi H.,Brain E.,Cardoso M.J.,Chibaudel B.,Coleman R.,Cufer T.,Dal Lago L.,Dalenc F.,De Azambuja E.,Debled M.,Delaloge S.,Filleron T.,Gligorov J.,Gutowski M.,Jacot W.,Kirkove C.,MacGrogan G.,Michiels S.,Negreiros I.,Offersen B.V.,Penault Llorca F.,Pruneri G.,Roche H.,Russell N.S.,Schmitt F.,Servent V.,Thürlimann B.,Untch M.,van der Hage J.A.,van Tienhoven G.,Wildiers H.,Yarnold J.,Bonnetain F.,Mathoulin-Pélissier S.,Bellera C.,Dabakuyo-Yonli T.S.
Reference17 articles.
1. End points and United States Food and Drug Administration approval of oncology drugs;Johnson;J Clin Oncol Off J Am Soc Clin Oncol,2003
2. International conference on harmonisation; guidance on statistical principles for clinical trials; availability—FDA. Notice;Fed Regist,1998
3. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials;Schulz;Ann Intern Med,2010
4. Survival end point reporting in randomized cancer clinical trials: a review of major journals;Mathoulin-Pélissier;J Clin Oncol Off J Am Soc Clin Oncol,2008